Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024
Period Ending	Jun 30, 2025	Dec 31, 2024
Cash & Equivalents	65.4	61.58
Short-Term Investments	263.01	314.07
Cash & Short-Term Investments	328.41	375.65
Prepaid Expenses	3.61	1.22
Total Current Assets	332.01	376.87
Property, Plant & Equipment	2.25	1.04
Long-Term Investments	23.05	18.07
Other Long-Term Assets	0.1	0.04
Total Assets	357.42	396.02
Accounts Payable	4.66	3.46
Accrued Expenses	3.7	9.37
Current Portion of Leases	0.66	0.21
Total Current Liabilities	12.11	13.04
Long-Term Leases	1.67	0.76
Total Liabilities	13.78	13.8
Common Stock	0.04	0.04
Additional Paid-In Capital	470	463.02
Retained Earnings	-129.3	-83.72
Comprehensive Income & Other	-0.03	-0.04
Total Common Equity	340.71	379.29
Shareholders' Equity	343.64	382.22
Total Liabilities & Equity	357.42	396.02
Total Debt	2.33	0.97
Net Cash (Debt)	349.13	392.75
Net Cash Per Share	9.66	23.39
Filing Date Shares Outstanding	37.45	37.44
Total Common Shares Outstanding	37.45	37.44
Working Capital	319.9	363.83
Book Value Per Share	9.10	10.13
Tangible Book Value	340.71	379.29
Tangible Book Value Per Share	9.10	10.13

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q